olivLaw · European equity research
Biohit Oyj BIOBV.HE
Finland · Nasdaq Helsinki · Vertical: Listed companies from Finland
Biohit Oyj is a Finnish group focused on intestinal tract expertise, headquartered in Helsinki with shares listed on Nasdaq Helsinki. In fiscal 2025 revenue rose by 10.1%, and the company proposes no dividend for 2025.
At the close of 05 Nov 2026, Biohit Oyj (BIOBV.HE) stock was 2.20 EUR (+0.00% on the day), with market capitalisation 334.6 k EUR, P/E 0.1 on diluted EPS of 18.00 EUR over the last 12 months, beta 0.33, 52-week range 2.08–3.70 EUR.
Data as of · AI analysis dated · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 47.1
- neutral
- Bollinger (20, 2)
- 2.04 – 2.32
- in the upper half of the band · %B 0.57 · band width 12.5%
- SMA 50 / 200
- 2.33 / 2.57
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.05 / -0.07
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | −6.8% | +0.4% | −7.2 pp | — |
| 3 months | −18.5% | −3.3% | −15.3 pp | — |
| 6 months | −10.2% | +4.0% | −14.2 pp | — |
| Year to date | −40.4% | +8.1% | −48.5 pp | — |
| 1 year | −26.4% | +10.7% | −37.1 pp | −1.2% |
| 3 years | +13.1% | +50.1% | −37.0 pp | +4.1% |
| 5 years | +10.0% | +43.6% | −33.6 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 0 percentile of its own 3-quarter history (min 0.1, median 0.2, max 15.7; quarters with earnings only).
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 13.1 m | 14.3 m | 15.7 m |
| Revenue YoY | unavailable | +9.2% | +10.1% |
| Net income | 1.9 m | 2.6 m | 2.7 m |
| Net income YoY | unavailable | +38.7% | +6.6% |
| Diluted EPS | 0.12 | 17.00 | 18.00 |
| Diluted EPS YoY | unavailable | +14,066.7% | +5.9% |
| net % | 14.2% | 18.0% | 17.4% |
| Free cash flow | unavailable | unavailable | unavailable |
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 3.5 m EUR
- Financial debt
- unavailable EUR
- Net debt
- unavailable EUR
- Equity
- 14.9 m EUR
- Total assets
- 19.8 m EUR
- Debt / equity
- unavailable
- Current ratio
- 2.56x
- ROE
- 20.2%
- ROA
- 15.5%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (EUR)
Margins
Income statement · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 13.1 m | 14.3 m | 15.7 m | esef· 18 Mar 2026verified |
| Operating income | 1.8 m | 2.6 m | 2.9 m | esef· 18 Mar 2026verified |
| Interest expense | 159.0 k | 322.0 k | 140.0 k | esef· 18 Mar 2026verified |
| Pre-tax income | 2.2 m | 2.9 m | 2.9 m | esef· 18 Mar 2026verified |
| Income tax | 344.0 k | 299.0 k | 163.0 k | esef· 18 Mar 2026verified |
| Net income | 1.9 m | 2.6 m | 2.7 m | esef· 18 Mar 2026verified |
| Diluted EPS | 0.12 | 17.00 | 18.00 | esef· 18 Mar 2026verified |
Balance sheet · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 3.3 m | 3.7 m | 3.5 m | esef· 18 Mar 2026verified |
| Receivables | 4.1 m | 3.2 m | 3.6 m | esef· 18 Mar 2026verified |
| Inventories | 890.0 k | 1.0 m | 799.0 k | esef· 18 Mar 2026verified |
| Current assets | 11.8 m | 11.0 m | 9.2 m | esef· 18 Mar 2026verified |
| Property, plant & equipment, net | 140.0 k | 171.0 k | 355.0 k | esef· 18 Mar 2026verified |
| Intangibles (excl. goodwill) | 183.0 k | 492.0 k | 710.0 k | esef· 18 Mar 2026verified |
| Total assets | 12.9 m | 15.5 m | 19.8 m | esef· 18 Mar 2026verified |
| Current liabilities | 3.1 m | 3.0 m | 3.6 m | esef· 18 Mar 2026verified |
| Equity | 9.4 m | 12.2 m | 14.9 m | esef· 18 Mar 2026verified |
| Shares outstanding at year end | 15.4 m | 151.1 k | 152.1 k | esef· 18 Mar 2026derived |
Cash flow · EUR
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 27.1% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 334.6 k EUR
Key indicators
Coverage and freshness
Score by group
27% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 159.63 – 332.99 EUR.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (EUR per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/E159.63 – 332.99 (Mid 209.14)23 companies used · median multiple 11.6x · quartiles 8.9x – 18.5xALMA.HE, APETIT.HE, ASPO.HE, ATRAV.HE, CAPMAN.HE, CONSTI.HE, DIGIA.HE, ELEAV.HE, ELISA.HE, ENENTO.HE, ETTE.HE, FORTUM.HE, FSECURE.HE, GLA1V.HE, GRK.HE, HARVIA.HE, ICP1V.HE, ILKKA.HE, INVEST.HE, KALMAR.HE, KAMUX.HE, KCR.HE, KEMIRA.HE
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Assumptions (illustrative, editorial)
- Risk-free rate
- 3.0%
- Equity risk premium
- 5.5%
- Beta (default)
- 1.00
- Cost of equity
- 8.5%
- Terminal growth
- 2.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 17.4% | 90 (vs peers) | 23% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 20.9x | 100 (on a fixed band) | 23% |
| Current ratio · Balance sheet | 2.6x | 100 (on a fixed band) | 15% |
| P/E (TTM) · Valuation | 0.1x | 96 (vs peers) | 38% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet100/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partial90/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial96/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Biohit Oyj (BIOBV.HE). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 15.7 m EUR in 2025; YoY growth 10.1%; net margin 17.4%; ROE 20.2%.
The estimated value range is 159.62–332.99 EUR per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 209.14 EUR, the price of 2.20 EUR leaves a potential of 9,406.5% (value / price − 1) and a margin of safety of 98.9% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 17.4%
- Interest coverage: 20.9x
- Current ratio: 2.6x
- P/E (TTM): 0.1x
- The price is below the estimated value range
What contradicts it
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Listed companies from Finland · same country · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| FORTUM.HEFortum Oyj | 20.8 bn | 27.2 | 8.7% | 15.3% | −14.0% | +32% / +81% |
| ELISA.HEElisa Oyj | 5.6 bn | 16.3 | 27.0% | 15.2% | +3.0% | −8% / −15% |
| KEMIRA.HEKemira Oyj | 2.5 bn | 13.6 | 10.5% | 6.6% | −6.6% | −17% / +4% |
| KALMAR.HEKalmar Oyj | 2.4 bn | 14.7 | 24.1% | 9.4% | +1.2% | +0% / unavailable |
| KCR.HEKonecranes Oyj | 2.2 bn | 5.6 | 20.3% | 9.5% | −0.9% | −4% / +134% |
| EXEL.HEExel Composites Oyj | 1.8 bn | — | -18.5% | -5.3% | +3.6% | +163% / +74% |
| BITTI.HEBittium Oyj | 1.2 bn | 55.8 | 17.5% | 17.9% | +40.1% | +73% / +603% |
| ALMA.HEAlma Media Oyj | 1.2 bn | 21.2 | 23.0% | 16.9% | +4.6% | +9% / +57% |
| FIA1S.HEFinnair Oyj | 927.4 m | 50.4 | 2.9% | 0.6% | +1.9% | +54% / +22% |
| GRK.HEGRK Infra Oyj | 788.5 m | 18.3 | 27.8% | 4.9% | +19.7% | +52% / unavailable |
| HARVIA.HEHarvia Oyj | 768.7 m | 29.3 | 21.0% | 13.3% | +13.5% | −1% / +64% |
| ATRAV.HEAtria Oyj | 451.7 m | 11.1 | 9.8% | 2.2% | +3.3% | +13% / +57% |
| ANORA.HEAnora Group Oyj | 317.6 m | 57.8 | 1.4% | 0.8% | −4.9% | +26% / +11% |
| CAPMAN.HECapMan Oyj | 300.2 m | 23.1 | 6.8% | 20.9% | +9.4% | −8% / −20% |
| ICP1V.HEIncap Oyj | 261.0 m | 18.7 | 10.4% | 6.5% | −6.7% | −3% / +37% |
| FSECURE.HEF-Secure Oyj | 243.7 m | 10.9 | 43.4% | 15.3% | −0.4% | −17% / −23% |
| ASPO.HEAspo Oyj | 219.4 m | 9.3 | 15.4% | 5.0% | +2.1% | +2% / +9% |
| ETTE.HEEtteplan Oyj | 173.7 m | 16.4 | 8.8% | 2.9% | +0.1% | −27% / −51% |
| DIGIA.HEDigia Oyj | 131.6 m | 10.5 | 14.5% | 5.9% | +5.5% | −16% / −12% |
| ILKKA.HEIlkka Oyj | 93.8 m | 8.1 | 6.2% | 30.8% | +22.6% | +0% / +21% |
| CONSTI.HEConsti Oyj | 77.4 m | 11.6 | 15.3% | 2.0% | +2.9% | −8% / −6% |
| APETIT.HEApetit Oyj | 75.6 m | 8.4 | 8.2% | 5.4% | +3.1% | −14% / −3% |
| ESENSE.HEEnersense International Oyj | 74.9 m | 74.7 | 3.1% | 0.4% | −27.7% | +12% / +9% |
| CTH1V.HEComponenta Oyj | 66.1 m | 324.0 | 0.8% | 0.2% | −4.6% | +49% / +182% |
| KAMUX.HEKamux Oyj | 47.4 m | 10.3 | 4.2% | 0.5% | +0.8% | −40% / −77% |
1- and 3-year price returns: for BIOBV.HE from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (EUR)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 1.37 Total return -38% · Per year -38% | 2.42 Total return 10% · Per year 10% | 3.64 Total return 66% · Per year 66% |
| 3 years | 1.49 Total return -32% · Per year -12% | 2.94 Total return 34% · Per year 10% | 4.83 Total return 119% · Per year 30% |
| 5 years | 1.61 Total return -27% · Per year -6% | 3.57 Total return 62% · Per year 10% | 6.40 Total return 191% · Per year 24% |
- Exit P/E± 0.73
- Net margin± 0.51
- Annual revenue growth± 0.40
- Annual dilution± 0.04
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Biohit Oyj is a Finnish group focused on intestinal tract expertise, headquartered in Helsinki with shares listed on Nasdaq Helsinki. In fiscal 2025 revenue rose by 10.1% 1, and the company proposes no dividend for 2025 1.
SWOT
Strengths
Weaknesses
Opportunities
Threats
- Dependence on export markets and currency fluctuations, managed centrally by the parent company 1.
- Competition in the diagnostics industry, where large players may have greater resources.
- Regulatory risks and compliance requirements for medical products.
Risks
- Currency riskmedium
The company manages interest and exchange rate risks through the parent company's finance function 1. If currency swings grow larger, they could affect reported results.
- Shareholder concentrationmedium
The founder and a major Chinese shareholder hold a significant share of votes 1, which may limit the influence of minority shareholders.
- Reliance on subsidiariesmedium
Sales are mainly made through foreign subsidiaries 1. An operational failure in one of them could affect revenue.
- No dividendlow
The board does not propose a dividend for 2025 1, which may reduce interest from income-focused investors.
- Compliance and regulationhigh
Medical products are subject to strict quality and registration requirements, managed by a dedicated function 1. Any non-compliance could lead to costs or restrictions.
Investment thesis
What would need to be true (bull case)
- Revenue growth in fiscal 2025 1 may indicate solid demand, and if the pace holds, it could support expansion.
- The subsidiary sales network and the Chinese partnership provide access to several markets, which could support growth.
- The board structure and members' management experience may support execution of the long-term strategy.
What would break the thesis
- The absence of a dividend for fiscal 2025 1 may discourage investors seeking regular income.
- The concentration of votes among major shareholders may limit other shareholders' influence over decisions.
- Reliance on subsidiaries and medical regulation could slow expansion if problems arise.
What to watch
- Half-year financial report for January-June 20265 August 2026
- Annual general meeting and dividend decision3 June 2026
- Achieving balanced gender representation on the board30 June 2026
- Revenue growth trend in the next annual reportnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Biohit Oyj is a Finnish public limited company whose series B shares are listed on Nasdaq Helsinki in the Small cap/Healthcare group 1. The group includes the parent and foreign subsidiaries that mainly handle sales and marketing for Biohit Oyj's products 1. Its 2024-2028 strategy describes it as a global intestinal tract expert engaged in manufacturing, sales and marketing 1.
The board has five members, three of them independent, and the management team has six members 1. The auditor is PricewaterhouseCoopers Oy 1. Series A shares carry 20 votes each and series B shares one vote each 1.
Biohit is a small listed company with a significant shareholder base concentrated in its founder and in a major Chinese shareholder through Biohit Healthcare (Hefei) Co., Ltd. 1. The annual report indicates that subsidiaries play a central role in distribution in their markets 1.
Segments
Intestinal tract products
Biohit develops, manufactures and sells products related to the intestinal tract, according to its global strategy 1. The annual report in this source set does not break revenue down by product line 1.
Sales and marketing subsidiaries
Subsidiaries in the United Kingdom and Italy, led by managing directors, handle sales and marketing of products in their markets under the supervision of the President and CEO 1.
Market context
The company operates in intestinal diagnostics and products, selling through subsidiaries in several European countries and through a partnership in China 1. The annual report in this source does not give the total market size.
Revenue growth of 10.1% in fiscal 2025 1 points to expanding demand for the company's products, though whether this pace holds in later years remains to be seen.
Trends
- Sales growth in fiscal 2025tailwind
Revenue increased by 10.1% year on year 1, suggesting solid demand for the company's products. If the trend continues, it could support further investment in research and development.
- Focus on international expansionmixed
The 2024-2028 strategy emphasises global development of intestinal tract expertise, supported by the subsidiary network and the Chinese partnership 1. The effect depends on converting these markets into sales.
- Digitalisation and supply chainstailwind
Board members have experience in digitalising and optimising global supply chains 1, which could support operational efficiency if these practices are applied.
- No dividend proposedheadwind
The board proposes that the annual general meeting pay no dividend for fiscal 2025 1. For investors focused on dividend income, this is a negative factor in the short term.
Competitive position
The provided sources do not identify Biohit's direct competitors. The company works in intestinal diagnostics and products, where several international players are active, although their names do not appear in the annual report 1.
The company's competitive position depends on its network of sales subsidiaries and international partnerships, factors the annual report highlights 1. A precise market share assessment would require additional sources.
- Unnamed competitors in source
The annual report does not name competitors, so no verifiable name exists in the source.
- Intestinal diagnostics manufacturers
General competitive category, with no names specified in the provided sources.
- Regional medical product suppliers
Local competition in markets where Biohit subsidiaries sell, without data in the source.
- General biotechnology companies
Indirect competition, not detailed in the annual report reviewed.
News & filings
In the press
No news in our archive over the last 180 days.
Annual reports (ESEF)
- Annual report 202518 Mar 2026
- Annual report 202424 Sept 2025
Sources
- [1] Annual report, fiscal year ended 2025-12-31 (ESEF) · SEC / Biohit Oyj · 31 Dec 2025
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.